Phase 3 N=267 A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia
Hyperkalemia
Primary: Least Square Mean S-K Level on Days 8-29 — 4.811; 4.381; 5.321 mmol/L — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=880 Clinical Equivalence Study of Mometasone Nasal Spray
Seasonal Allergic Rhinitis
Primary: Change From Baseline in Average AM/PM Reflective Total Nasal Symptom Score (rTNSS) Over Days 1 to 14. — 1.861; 1.600 score on a scale
Phase 3 N=784 Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Depressive Disorder, Major
Primary: Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment — -17.09; -18.94; -21.95; -18.22 units on a scale — p=0.4702
Phase 3 N=193 Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia
Hematologic Diseases · Anemia, Sickle Cell
Primary: Treatment Differences of the Change in Qualitative Splenic Function From Baseline — 19; 28; 51; 46 Participants — p=0.21
Phase 3 N=2,272 Long Term Safety Study of Plecanatide
Irritable Bowel Syndrome
Primary: Number of Participants With Treatment Related Adverse Events. — 205 Participants
Phase 3 N=61 A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)
Parkinson's Disease (PD)
Primary: Mean Change From Baseline to Week 12 in Unified Dyskinesia Rating Scale (UDysRS) Total Score — -2.33; -17.37 units on a scale — p=<0.0001
Phase 3 N=773 A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV
Poliomyelitis
Primary: Seroconversion Non-inferiority of 2 Doses f-IPV ID vs 2 Doses IPV IM — 98.1; 95.9; 98.7; 97.9 percentage of seroconversion — p=0.05
Phase 3 N=808 Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery
Cataract
Primary: Number of Participants Without Signs of Anterior Chamber Inflammation — 376; 373; 19; 20 Participants
Phase 3 N=256 Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab
Lymphoma, Non-Hodgkin
Primary: Percentage of Participants Who Responded (Overall Response Rate - ORR) by Week 28 Based on Independent Central Assessment of Disease — 78.0; 70.2 percentage of…
Phase 3 N=317 Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Axial Spondyloarthritis · Nonradiographic Axial Spondyloarthritis · Nr-axSpA
Primary: Percentage of Subjects With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) Response Criteria Response at Week 52 — 7.0; 47.2 percentage of…
Phase 3 N=274 Hypovitaminosis D in Neurocritical Patients
Craniocerebral Trauma · Intracranial Aneurysm · Brain Neoplasms
Primary: Intent-to-treat Hospital Length-of-stay — 10.9; 9.1 days — p=0.2
Phase 3 N=250 Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea
HIV Enteropathy · Diarrhea With HIV
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs). — 189; 20 Participants
Phase 3 N=381 A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.
Bipolar I Disorder · Acute Mania
Primary: Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) by Severity — 79; 86; 60; 68 Participants
Phase 3 N=123 (CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.
Ulcerative Colitis
Primary: Percentage of Participants Achieving Clinical Remission — 76.7; 88.2; 92.0; 96.8 percentage of participants
Phase 3 N=941 Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)
Extreme Prematurity
Primary: Number of Participants With Death or Severe Neurodevelopmental Impairment (NDI) at 22-26 Months Corrected Age — 94; 97 Participants — p=0.05